Based on these results, we found that RCAN2 was significantly positively correlated with TC and TG in all participants, non-NAFLD subjects, and NAFLD patients, and had a closer correlation with TG, especially in all participants (r = 0.475, p = 0.000) and NAFLD patients (r = 0.458, p = 0.000). This evidence concerns the gene RCAN2 and metabolic dysfunction-associated steatotic liver disease.